Close Menu

NEW YORK (GenomeWeb) – Castle Biosciences today announced it has secured a $6 million credit facility from Silicon Valley Bank.

The funding will be used to support commercial and clinical activities for the firm's cutaneous melanoma test called DecisionDx-Melanoma for determining the metastatic risk of patients with melanoma, Castle President and CEO Derek Maetzold said in a statement. The financing will also be used for general operations. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.